MedWatch

Analyst: Partnership deals an option for Bavarian

The latest phase II data on Bavarian Nordic’s cancer vaccine CV-301 are great news, says analyst Frank H. Andersen. A later strategic portfolio assessment could lead to partnership deals.

Foto: Colourbox

It is certainly very good news the Danish company Bavarian Nordic announced concerning its vaccine candidate on Wednesday. That is the brief assessment from analyst Frank H. Andersen, Jyske Bank, who has previously told Medwatch he was keeping a close eye on the drug.

“CV-301 has been studied in various cancer indications, and it has also shown good data in regards to breast cancer. Now we are seeing good preliminary phase II data in regards to colon cancer, although they do not reveal exactly how much longer overall survival was,” he tells Medwatch and elaborates:

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier